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linkage to the Cl channel gene, CLCNKB, on chromosomeA novel mutation in the chloride channel gene, CLCNKB, as a
1p36. Mutation analysis by direct sequencing revealed a novelcause of Gitelman and Bartter syndromes.
homozygous missense mutation, arginine 438 to histidineBackground. Gitelman syndrome (GS) and Bartter syn-
(R438H), in exon 13 of CLCNKB in all patients. A restrictiondrome (BS) are hereditary hypokalemic tubulopathies with
fragment length polymorphism (RFLP) analysis has been de-distinct phenotypic features. GS has been considered a geneti-
veloped to aid in genotyping of family members.cally homogeneous disorder caused by mutation in the gene
Conclusions. Our findings demonstrate intrafamilial hetero-encoding the NaCl cotransporter (TSC) of the distal convo-
geneity, namely the presence of GS and CBS phenotypes, inluted tubule. In contrast, BS is caused by mutations in the
a kindred with the CLCNKB R438H mutation. We concludegenes encoding either the Na-K-2Cl cotransporter (NKCC2),
that GS can be caused by a mutation in a gene other thanthe K channel (ROMK) or the Cl channel (ClC-Kb) of the
thick ascending limb. The purpose of this study was to examine SLC12A3. The exact role of the CLCNKB R438H mutation
the clinical, biochemical and genetic characteristics of a very in the pathogenesis of the electrolyte and mineral abnormalities
large inbred Bedouin kindred in Northern Israel with heredi- in GS and CBS remains to be established.
tary hypokalemic tubulopathy.
Methods. Twelve family members affected with hypoka-
lemic tubulopathy, as well as 26 close relatives were clinically
Bartter syndrome is a group of closely related heredi-and biochemically evaluated. All study participants underwent
tary tubulopathies. All variants of the syndrome sharegenetic linkage analysis. Mutation analysis was performed in
affected individuals. several clinical characteristics including renal salt wasting,
Results. Evaluation of affected family members (age range hypokalemic metabolic alkalosis, hyperreninemic hyper-
3 to 36 years) revealed phenotypic features of both GS and
aldosteronism with normal blood pressure and hyperpla-classic Bartter syndrome (CBS). Features typical of GS in-
sia of the juxtaglomerular apparatus [1–3]. The syndromecluded late age of presentation (15 years) in 7 patients (58%),
normal growth in 9 (75%), hypomagnesemia (SMg0.7mmol/L) has been classified into three distinct phenotypes. First,
in 5 (42%), hypermagnesiuria (FEMg 5%) in 6 (50%) and hy- antenatal Bartter syndrome, also known as hyperprosta-
pocalciuria (urinary calcium/creatinine mmol/mmol 0.15) in glandin E syndrome, is the most severe form of the dis-
5 (42%). Features typical of CBS included early age of presen-
ease. It is characterized by polyhydramnios, prematuretation (1 year) in 3 (25%), polyuria/dehydration in 4 (33%),
birth, life threatening episodes of salt and water loss ingrowth retardation in 3 (25%), hypercalciuria (urinary calcium/
creatinine mmol/mmol 0.55) in 4 (33%) and nephrolithiasis the neonatal period, hypokalemic alkalosis and failure
in 1 (8%). Linkage analysis in affected patients excluded the to thrive, as well as hypercalciuria and early onset nephro-
TSC gene, SLC12A3, as the mutated gene, but demonstrated calcinosis [1, 2]. Second, classic Bartter syndrome occurs
in infancy or early childhood. It is characterized by marked
salt wasting and hypokalemia leading to polyuria, poly-1 Current address: National Institute on Deafness and other Communi-
cation Disorders, National Institute of Health, 5 Research Court, Room dipsia, volume contraction, muscle weakness, and growth
2A-02, Rockville, MD 20850, USA.
retardation. Hypercalciuria and nephrocalcinosis may2 Current address: Johnson and Johnson Pharmaceutical Research and
Development, 1000 Route 202, P.O. Box 300, Raritan, NJ 08869, USA. occur [2, 3]. Finally, Gitelman syndrome is characterized
by a milder clinical presentation in older children or adults
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[4]. Patients may be asymptomatic and present with tran-magnesium deficiency, phenotype, linkage (genetics), sequence analy-
sis, DNA, Bedouin kindred study. sient muscle weakness, abdominal pain, symptoms of
neuromuscular irritability, or unexplained hypokalemia.Received for publication May 13, 2002
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which are caused by mutations in the genes encoding ples for biochemical analyses were collected after appro-
priate informed consent was obtained from the subjectsthe luminal Na-K-2Cl cotransporter, NKCC2 [5], the
luminal K channel, ROMK [6], and the basolateral Cl or their guardian. Serum levels of potassium, creatinine,
calcium and magnesium as well as plasma bicarbonatechannel, ClC-Kb [7], respectively, of the thick ascending
limb of the loop of Henle (TAL). In contrast, Gitelman level were analyzed using standard laboratory automated
techniques. Urine was collected for analysis of calcium,syndrome, which has been considered a genetically ho-
mogenous disorder, is caused by mutations in the gene magnesium and creatinine levels. Calcium excretion was
expressed as the urinary calcium/creatinine ratio and mag-encoding the thiazide-sensitive NaCl cotransporter, TSC,
of the distal convoluted tubule (DCT) [8]. nesium excretion was expressed as fractional excretion
of magnesium.With respect to genotype-phenotype correlation, it
has been widely accepted that patients with the NKCC2
Genetic linkage analysis[5, 9, 10] or ROMK [6, 11, 12] defect usually have the se-
vere antenatal form, those with the ClC-Kb defect have Genomic DNA was extracted from peripheral blood
lymphocytes of family members by using standard meth-the classic form [7], and the TSC defect leads to Gitelman
syndrome [8, 13]. ods [19]. Linkage analysis was performed using 4-6 dinu-
cleotide repeat (CA) markers from the Genethon micro-Recent data, however, have suggested that the geno-
type-phenotype correlation is not so clear-cut and that satellite panel [20] tightly linked to each of the following
three genetic loci: Na-K-2Cl cotransporter gene (SLC-phenotypic overlap may occur. Konrad et al [14] and Jeck
et al [15] reported that mutations in the ClC-Kb gene, 12A1), thiazide-sensitive NaCl cotransporter gene (SLC-
12A3) and voltage-gated Cl channel gene (CLCNKB).CLCNKB, also can cause phenotypes that overlap with
either antenatal Bartter syndrome or Gitelman syndrome. The following markers were used: D15S132, D15S1017,
D15S978, D15S126, D15S121, D15S209 (for SLC12A1),Recently, an additional variant of antenatal Bartter syn-
drome associated with sensorineural deafness and renal D16S408, D16S3140, D16S3071, D16S494 (for SLC12A3)
and D1S2672, D1S507, D1S2697, D1S436 (for CLCNKB).failure has been described [16]. This variant is caused by
mutations in the BSND gene, which encodes the integral Genotyping of the markers was performed by use of a
non-radioactive–labeling procedure with the enhancedmembrane protein barttin [17], a -subunit for voltage-
gated (CLC) Cl channels [18]. chemiluminescence (ECL) system (Amersham, Braun-
schweig, Germany), on the basis of a horseradish peroxi-The purpose of the current study was to shed addi-
tional light upon this phenotypic heterogeneity by exam- dase-mediated chemiluminescent reaction [21].
ining the clinical, biochemical and genetic characteristics
Mutation analysis by direct sequencingof a very large inbred Bedouin kindred in Northern Israel
with hereditary hypokalemic tubulopathy, in which a Nineteen pairs of oligonucleotide primers were gener-
ated to amplify by polymerase chain reaction (PCR) allwide spectrum of phenotypic features in affected patients
has been noted. 19 exons of the CLCNKB gene according to data ob-
tained from Simon et al [7]. PCR-amplified coding re-
gions as well as exon-intron boundaries were sequenced.
METHODS
PCR conditions for genomic amplification were as fol-
Patients lows: Denaturation at 94C for two minutes; 35 subse-
quent amplifications cycles performed at 94C for 30 sec-A large inbred Bedouin family residing in two close
villages in the lower Galilee was investigated. Twelve onds, 55C for 30 seconds and 72C for seven minutes.
Amplified DNA fragments were analyzed by electropho-members of the family were identified as having hypoka-
lemic tubulopathy. The pedigree of the kindred is shown resis on 2% agarose gels and purified using the QIAquick
gel extraction kit. Then, purified PCR products werein Figure 1. The family has lived in the same area for
more than two centuries. The pattern of inheritance of sequenced using capillary electrophoresis on an ABI
PRISM 310 automated sequencer (Perkin Elmer, War-the disease in the family is compatible with an autosomal
recessive trait. Twelve family members affected with hy- rington, UK) using the Big Dye terminator cycle se-
quencing kit (Perkin Elmer). Mutation analysis was per-pokalemic tubulopathy and 26 close relatives were in-
cluded in this study. At the time of enrollment, therapy formed in ten of the twelve affected family members.
of patients included various combinations of potassium
Restriction fragment length polymorphism analysissupplements, amiloride and spironolactone. No patient
received magnesium supplementation. Restriction fragment length polymorphism (RFLP)
analysis of exon 13 of CLCNKB was performed. PCR-
Phenotype analysis amplified DNA fragments containing the locus mutated
in this family were digested with the restriction enzymeClinical data were obtained from the patients, their
parents and their care providers. Blood and urine sam- Kas I and electrophoresed on a 2% agarose gel.
Fig. 1. Extended pedigree of a Bedouin family with hypokalemic tubulopathy. Filled squares (males) and circles (females) indicate affected
individuals. Deceased individuals are indicated by a diagonal line. The autosomal recessive mode of inheritance is evident.
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Table 1. Clinical features in affected patients
Age Age at presentation
History of Presence of
Patient/pedigree no. years Growth polyuria/dehydration nephrolithiasis
MZ/7 21 17 Normal No No
RZ/9 28 20 Normal No No
YZ/27 21 20 Normal No No
NZ/6 36 24 Retarded No No
MZ/10 32 20 Retarded No No
YZ/1 31 25 Normal Yes Yes
MZ/2 23 10 Normal Yes No
MZ/12 10 4 Normal Yes No
IZ/3 3 0.5 Retarded Yes No
MZ/5 7 0.3 Normal No No
NZ/13 3 0.1 Normal No No
BZ/14 31 29 Normal No No
Table 2. Laboratory findings in affected patients
Serum K Plasma HCO3 Serum Mg FEMg Urinary Ca/Cr
mEq/L mEq/L mmol/L % mmol/mmol
Patient/pedigree no. (nl 3.5–5.3) (nl 22–26) (nl 0.7–1.2) (nl 5%) (nl 0.15–0.55)
MZ/7 3.1 27 0.65 2.6 0.08
RZ/9 2.5 30 0.95 8.9 0.64
YZ/27 2.3 32 0.85 4.9 0.34
NZ/6 2.8 30 0.6 5.3 0.05
MZ/10 3.0 28 0.8 2.5 0.17
YZ/1 2.9 35 0.6 8.8 0.14
MZ/2 2.7 33 0.6 4.3 0.11
MZ/12 3.1 27 0.9 6.7 0.62
IZ/3 3.0 28 0.8 9.0 1.70
MZ/5 2.8 32 0.75 3.5 0.11
NZ/13 2.9 27 0.8 7.5 0.84
BZ/14 3.4 35 0.65 4.1 0.22
FEMg is fractional excretion of magnesium.
Table 3. Summary of phenotypic features in affected patientsRESULTS
Number ofClinical and biochemical characteristics
Feature patients %
Tables 1 and 2 summarize the clinical features and
Features typical of Gitelman syndromelaboratory findings in the 12 affected family members. Late age of presentation ( 15 years) 7 58
Age at enrollment in the study ranged from 3 years to Normal growth 9 75
Hypomagnesemia (SMg  0.7 mmol/L) 5 4236 years (median 21 years). Age at initial presentation
Hypermagnesiuria (FEMg  5%) 6 50ranged from one month to 29 years (median 17 years).
Hypocalciuria [urinary Ca/Cr
There were seven males and five females. All patients (mmol/mmol)  0.15] 5 42
Features typical of classic Bartter syndromehad normal blood pressure and normal glomerular fil-
Early age of presentation (1 year) 3 25tration rate. No patient had diarrhea during the study
Polyuria/dehydration 4 33period. The clinical and biochemical evaluation revealed Growth retardation 3 25
phenotypic features of both Gitelman syndrome (GS) Hypercalciuria [urinary Ca/Cr
(mmol/mmol)  0.55] 4 33and classic Bartter syndrome (CBS; Table 3). Features
Nephrolithiasis 1 8typical of GS included late age at presentation (15
Abbreviations are: SMg, serum magnesium; FEMg, fractional excretion of mag-years) in seven patients, normal growth in nine, hypo-
nesium; Ca/Cr, calcium, creatinine.
magnesemia (SMg0.7mmol/L) in five, hypermagnesiuria
(FEMg 5%) in six and hypocalciuria (calcium/creatinine
mmol/mmol 0.15) in five. Features typical of CBS in-
calciuria (Table 2), typical findings in GS, four had con-cluded early age of presentation (1 year) in three, his-
comitant hypomagnesemia and hypocalciuria. However,tory of polyuria and episodes of dehydration in four,
generally, the group of affected patients could not begrowth retardation in three, hypercalciuria (urinary cal-
subdivided into the “GS group” and the “CBS group,”cium/creatinine mmol/mmol0.55) in four and nephroli-
because the distinctive clinical/biochemical features ofthiasis in one patient.
Of the six patients with hypomagnesemia and/or hypo- either GS or CBS did not segregate in the same patient.
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The same patient could have features of both GS and
CBS. Nevertheless, five of the affected patients (pedigree
numbers 1, 3, 6, 9 and 10) have been generally character-
ized by a more severe form of the disease including
hypokalemia more resistant to therapy, frequent muscle
symptoms, frequent hospitalizations, growth retardation,
as well as polyuria and recurrent episodes of dehydra-
tion. There were no known cases with features of ante-
natal Bartter syndrome (such as polyhydraoannios, pre-
mature birth, manifestations in the neonatal period) and
no reported cases of unexpected mortality in this family.
Linkage analysis
Linkage analysis using the appropriate microsatellite
markers (Methods section) flanking the loci of the genes
encoding the Na-K-2Cl cotransporter (SLC12A1)
and the thiazide-sensitive NaCl cotransporter (SLC12A3)
did not reveal regions of homozygosity at these loci (data
not shown). Figure 2 shows the results of haplotype anal-
ysis using microsatellite markers linked to the CLCNKB
locus on chromosome 1p36. For all affected individuals
in the six subfamilies of this large kindred, regions of
homozygosity by descent were observed for this genomic
region, which was then further analyzed.
Mutation analysis
The linkage analysis data prompted a search for muta-
tions in the CLCNKB gene. Mutation analysis revealed
a novel homozygous missense mutation, guanine to ade-
nine in exon 13 of CLCNKB (Fig. 3). The mutation sub-
stitutes arginine with histidine (R438H) at amino acid
438 of the channel protein. All ten affected individuals
tested were found to carry the same mutation, homozy-
gous by decent from their related heterozygous parents.
RFLP analysis
Restriction fragment length polymorphism analysis of
PCR-amplified fragments in exon 13 of CLCNKB con-
taining the mutated locus in this family was performed.
The R438H mutation in the variant allele in this family re-
sults in the loss of Kas I restriction enzyme site. As shown
in Figure 4, the presence of the R438H mutation could
be detected by RFLP analysis.
Fig. 2. Linkage analysis in six subfamilies of the large kindred with
hypokalemic tubulopathy. Filled squares (males) and circles (females)
indicate affected individuals. Each individual within the kindred is num-
bered below the symbol. Haplotype analysis using microsatellite mark-
ers (shown on the left side) linked to the CLCNKB locus on chromosome
1p36 demonstrated cosegregation of the phenotype with the CLCNKB
locus. Regions of homozygosity are framed.
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Fig. 4. Restriction fragment length polymorphism (RFLP) analysis of
polymerase chain reaction-amplified fragment in exon 13 of CLCNKB
containing the locus mutated in this family. The numbers correspond
to the number of the individual within the kindred (see Figs. 1 and 2).
The cleavage site of the restriction enzyme Kas I in the wild-type 773 bp
fragment is eliminated by the R438H mutation. Healthy individuals
(wild-type) have two fast migrating bands, affected patients, homozy-
gotes for the mutation (Mutant), have a single, slower migrating band
and heterozygotes for the mutation have a three band pattern: two,
fast migrating bands and one, slow migrating band.
Gitelman syndrome and classic Bartter syndrome can
be distinguished by their characteristic phenotypic fea-
tures, which include late age, benign course and presence
of hypomagnesemia and hypocalciuria in the former and
early onset, polyuria, volume contraction, failure to thrive
and hypercalciuria in the latter [1–3]. Mutations in the
thiazide-sensitive NaCl cotransporter gene, SLC12A3,
on chromosome 16 have been found in nearly all GS
patients studied [8, 13, 22]. On the other hand, in most
patients with CBS, the molecular defect has been identi-
fied as a mutation in the voltage-gated Cl channel gene,
CLCNKB, on chromosome 3 [7, 15].
The clinical and biochemical evaluation of affected
members of the family reported here has revealed phe-
notypic features of both GS and CBS. An additional in-
teresting characteristic of this family was the fact that,
generally, the features of either GS or CBS did not segre-
Fig. 3. Mutation analysis by direct sequencing in family members af-
gate in the same patient. Phenotypic features of both GSfected with hypokalemic tubulopathy. The sequence in the mutation
area for healthy individuals (A), heterozygotes (B) and affected ho- and CBS could be found in the same patient. In contrast to
mozygotes (C ) is listed below the histograms. The analysis reveals a the observed phenotypic heterogeneity within the family,
novel homozygous missense mutation, guanine to adenine, in exon 13 of
all affected family members were found to have the sameCLCNKB. The mutation substitutes arginine with histidine (R438H)
at amino acid 438 of the channel protein. genetic defect, a missense R438H mutation in exon 13
of the voltage-gated Cl channel gene, CLCNKB.
Recent studies have provided evidence for phenotypic
overlap between the various forms of Bartter syndromeDISCUSSION
including CBS and GS. Bettinelli et al, who studied 34This study describes the clinical, biochemical and ge-
children with primary hypokalemic tubulopathy from 15netic characteristics of the largest consanguineous kin-
centers in Central Europe, reported failure to thrive indred affected with hereditary hypokalemic tubulopathy
20% of the patients with GS phenotype and found hypo-reported to date. This study not only provides evidence
magnesemia in one third of the children with BS pheno-that the genotype-phenotype correlation in Bartter/Git-
type [23]. Thurman reported the concomitant occurrenceelman syndrome is blurred, but also provides a unique
of Gitelman and Bartter syndromes in the same familyopportunity to demonstrate the phenotypic variability of
[24]. The author described two siblings presenting withthis syndrome in members of the same family bearing the
same genetic defect. normotensive hypokalemic alkalosis. One child had hy-
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pomagnesemia and hypocalciuria whereas the other had curs primarily via the luminal, thiazide-sensitive NaCl
cotransporter (TSC) [3, 25, 26]. Chloride exit to bloodnormal serum magnesium and urinary calcium excretion.
These two reports, however, did not include a genetic is mediated via basolateral Cl channels. The main path-
way of Cl exit from cell to blood in the distal tubule ap-analysis of affected patients. Simon et al, in their first
report on CLCNKB mutation in 17 kindreds with Bartter pears to be ClC-Kb channels, which are known to be
expressed at the basolateral membrane of the TAL andsyndrome type III, noted the marked variation in severity
of clinical features of affected patients ranging from pro- the DCT [27–29]. Hence, a defect in the activity of
ClC-Kb is expected to cause a reduction in NaCl reab-found hypokalemia and severe volume depletion to mild
disease presenting at the second decade of life [7]. Kon- sorption in these tubule segments. Nevertheless, alterna-
tive routes for Cl transport such as KCl cotransporter,rad and coworkers, who screened children with Bartter’s
syndrome from 30 families for CLCNKB mutations, CFTR or the voltage-gated Cl channel CLC5 [30–32],
may participate in basolateral Cl exit. Of great interestshowed that mutations in this gene most commonly cause
the classic Bartter syndrome [15]. Nevertheless, in a mi- is the recent identification of barttin, a Cl channel
-subunit that colocalizes with the channel in basolateralnority of patients, various mutations in CLCNKB were
found to cause phenotypes that overlapped with either membranes of the renal tubule and inner ear epithelium
[17, 18]. Barttin appears to mediate basolateral recyclingantenatal Bartter syndrome or Gitelman syndrome. Re-
cently, Jeck et al reported three patients whose clinical of Cl [18].
The summary of these interrelated transport processescourse was characterized by gradual transition from CBS
to GS phenotype, and who were found to carry three leads to the hypothesis that variation in expression and/or
function of any one of the channels or transporters par-different mutations in the CLCNKB gene [15].
The findings of these studies demonstrating the pheno- ticipating in Cl transport in the TAL and the DCT may
modify to variable degrees the derangement in ClC-Kbtypic variability associated with CLCNKB mutations could
be potentially attributed to the nature of the genetic de- function, thereby influencing the disease phenotype. Such
a modifying effect could occur at the cellular/regulatoryfect. For example, differences in the type and/or location
of the mutation within the gene could result in differ- level, whereby one or more transport mechanisms are re-
cruited to compensate for impaired ClC-Kb function or,ences in the magnitude of the loss of function of the Cl
channel, thereby resulting in differences in clinical pic- alternatively, may be determined at the level of modifier
genes. Our linkage analysis studies have provided no evi-tures. Alternatively, age-related alterations in the activ-
ity of the defective Cl channel could lead to a gradual dence that the phenotypic variability in our family was
related to a defect in the Na-K-2Cl cotransporter gene,transition from one phenotype to the other, as demon-
strated by Jeck et al in their longitudinal observation of SLC12A1 or the thiazide-sensitive NaCl cotransporter
gene, SLC12A3. Obviously, further genetic analysis ofthree patients [15]. These considerations, however, do not
apply to the family reported here, in which the phenotypic the family, in an effort to identify such a modifier gene,
would be of great importance. Such a study also shoulddifferences have been observed in a cross-sectional study
in patients bearing the same missense homozygous muta- include a careful analysis of genetic polymorphism in
various loci relevant to renal tubular ion transport.tion presumably originating in a common ancestor.
How could a specific genetic defect in CLCNKB result Hypomagnesemia and/or hypocalciuria, both typical
findings in Gitelman syndrome [3, 33], occurred in sixin such a wide range of clinical phenotypes within the
same family? Examination of the nature of Cl transport (50%) of the affected family members. Of these, four had
concomitant hypomagnesemia and hypocalciuria. Thein the distal parts of the renal tubule potentially could
provide an explanation for this phenomenon. Trans- hypomagnesemia was mild as previously noted in pa-
tients with CLCNKB mutations who had this laboratoryepithelial Cl transport in the TAL is a complex process
that involves the coordinated interplay between the lu- abnormality. The exact mechanisms underlying the hy-
pocalciuria and hypomagnesemia in Gitelman syndromeminal, bumetanide-sensitive Na-K-2Cl cotransporter
(NKCC2), the luminal, adenosine 5-triphosphate (ATP)- are unclear. It has been hypothesized that the loss of
function mutation in TSC causes hypocalciuria by theregulated, inwardly-rectifying K channel (ROMK), the
basolateral Cl channel (ClC-Kb), as well as other co- same mechanism as thiazide diuretics. According to this
hypothesis, impaired Na reabsorption across the lumi-transporters and channels [3, 25, 26]. Chloride is re-
absorbed across the luminal membrane of the TAL cell nal membrane of the distal convoluted tubular cell, cou-
pled with continued exit of intracellular Cl throughby the activity of NKCC2. This cotransporter is driven
by the low intracellular Na and Cl concentrations gen- basolateral Cl channels, causes the cell to hyperpolar-
ize. This, in turn, stimulates entry of calcium into theerated by the basolateral Na-K-ATPase and ClC-Kb,
respectively. In addition, ROMK enables the functioning cell via luminal voltage-activated Ca channels [34]. In
addition, the lowering of intracellular Na concentrationof NKCC2 by recycling K back to the renal tubular
lumen. Cl transport in the distal convoluted tubule oc- facilitates Ca exit via basolateral Na/Ca exchanger.
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characterized by hypokalemia and hypomagnesaemia. Trans AssocThe mechanisms whereby a CLCNKB mutation decreases
Am Physicians 79:221–235, 1966
Ca excretion in the urine, as observed in our patients, 5. Simon DB, Karet FE, Hamdan JM, et al: Bartter’s syndrome:
Hypokalemic alkalosis with hypercalciuria, is caused by muta-are unclear. It is possible that impaired Cl exit at the
tions in the Na-K-2C1 cotransporter NKCC2. Nat Genet 13:183–basolateral membrane of the DCT and subsequent intra-
188, 1996
cellular accumulation of Cl directly or indirectly influ- 6. Simon DB, Karet FE, Rodriguez-Soriano J, et al: Genetic hetero-
geneity of Bartter’s syndrome revealed by mutations in the Kence DCT cell function, thereby increasing Ca reab-
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III. Nat Genet 17:171–178, 1997drome, in general, and the role of the ClC-Kb defect
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of Bartter’s syndrome, inherited hypokalemic alkalosis, is caused
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9. Vargas-Poussou R, Feldman D, Vollmer M, et al: Novel mo-channel defect, as observed in our family, specific mecha-
lecular variants of the Na-K-2C1 cotransporter gene are responsi-
nisms are activated that compensate for the derangement ble for antenatal Bartter syndrome. Am J Hum Genet 62:1332–
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10. Kurtz CL, Karolyi L, Seyberth HW, et al: A common NKCC2hypomagnesemia and hypocalciuria. Moreover, some
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Syndromes: Mutations in the gene encoding the inwardly rectifyinga subject for further investigation.
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In summary, our findings demonstrate intrafamilial het- Bartter syndrome: Evidence for genetic heterogeneity. Hum Mol
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